Cargando…

Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature

Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Enchong, Shiori, Fujisawa, Mu, Oscar YongNan, He, Jieqian, Ge, Yuntian, Wu, Hongliang, Zhang, Mo, Song, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940376/
https://www.ncbi.nlm.nih.gov/pubmed/33708770
http://dx.doi.org/10.3389/fcell.2021.639615
_version_ 1783661940640317440
author Zhang, Enchong
Shiori, Fujisawa
Mu, Oscar YongNan
He, Jieqian
Ge, Yuntian
Wu, Hongliang
Zhang, Mo
Song, Yongsheng
author_facet Zhang, Enchong
Shiori, Fujisawa
Mu, Oscar YongNan
He, Jieqian
Ge, Yuntian
Wu, Hongliang
Zhang, Mo
Song, Yongsheng
author_sort Zhang, Enchong
collection PubMed
description Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk-CpG sites. Using an unsupervised clustering analysis, called consensus clustering, we found that patients with PCa could be divided into two subtypes (Methylation_H and Methylation_L) based on the DNA methylation status at these CpG sites. Differences in the epigenome, genome, transcriptome, disease status, immune cell composition, and function between the identified subtypes were explored using The Cancer Genome Atlas database. This analysis clearly revealed the risk characteristics of the Methylation_H subtype. Using a weighted correlation network analysis to select risk-related genes and least absolute shrinkage and selection operator, we constructed a prediction signature for prognosis based on the subtype classification. We further validated its effectiveness using four public datasets. The two novel PCa subtypes and risk predictive signature developed in this study may be effective indicators of prognosis.
format Online
Article
Text
id pubmed-7940376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79403762021-03-10 Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature Zhang, Enchong Shiori, Fujisawa Mu, Oscar YongNan He, Jieqian Ge, Yuntian Wu, Hongliang Zhang, Mo Song, Yongsheng Front Cell Dev Biol Cell and Developmental Biology Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk-CpG sites. Using an unsupervised clustering analysis, called consensus clustering, we found that patients with PCa could be divided into two subtypes (Methylation_H and Methylation_L) based on the DNA methylation status at these CpG sites. Differences in the epigenome, genome, transcriptome, disease status, immune cell composition, and function between the identified subtypes were explored using The Cancer Genome Atlas database. This analysis clearly revealed the risk characteristics of the Methylation_H subtype. Using a weighted correlation network analysis to select risk-related genes and least absolute shrinkage and selection operator, we constructed a prediction signature for prognosis based on the subtype classification. We further validated its effectiveness using four public datasets. The two novel PCa subtypes and risk predictive signature developed in this study may be effective indicators of prognosis. Frontiers Media S.A. 2021-02-23 /pmc/articles/PMC7940376/ /pubmed/33708770 http://dx.doi.org/10.3389/fcell.2021.639615 Text en Copyright © 2021 Zhang, Shiori, Mu, He, Ge, Wu, Zhang and Song. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Zhang, Enchong
Shiori, Fujisawa
Mu, Oscar YongNan
He, Jieqian
Ge, Yuntian
Wu, Hongliang
Zhang, Mo
Song, Yongsheng
Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
title Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
title_full Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
title_fullStr Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
title_full_unstemmed Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
title_short Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature
title_sort establishment of novel dna methylation-based prostate cancer subtypes and a risk-predicting eight-gene signature
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940376/
https://www.ncbi.nlm.nih.gov/pubmed/33708770
http://dx.doi.org/10.3389/fcell.2021.639615
work_keys_str_mv AT zhangenchong establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT shiorifujisawa establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT muoscaryongnan establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT hejieqian establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT geyuntian establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT wuhongliang establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT zhangmo establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature
AT songyongsheng establishmentofnoveldnamethylationbasedprostatecancersubtypesandariskpredictingeightgenesignature